相关实验视频

Updated: May 8, 2025

Assessment of Memory Function in Pilocarpine-induced Epileptic Mice

Assessment of Memory Function in Pilocarpine-induced Epileptic Mice

Published on: June 4, 2020

迪皮里达摩尔改善记忆障碍,并增加海马 Calbindin 表达在尼曼选择C1小鼠

Lucia Gaddini¹, Valentina Chiodi¹, Andrea Matteucci¹

¹National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.

Journal of neuroscience research

|December 24, 2024

概括

狄皮里达摩尔 (DIP) 对尼曼-皮克型C1 (NPC1) 疾病有前景,改善了小鼠的认知缺陷. 然而,在这种罕见的遗传性疾病中,DIP没有影响运动功能或外周器官病理.

科学领域:

神经科学是一个神经科学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

尼曼-皮克型C1 (NPC1) 是一种罕见的,致命的溶酶体储存障碍.
NPC1导致脂质积累,损害中枢神经系统和外周器官.
目前对NPC1的治疗方法有限,需要新的治疗策略.

研究的目的:

在尼曼-皮克型C1 (NPC1) 的小鼠模型中评估二皮里达摩尔 (DIP) 的体内疗效.
评估DIP对NPC1小鼠认知功能,运动技能和病理学的影响.

主要方法:

在NPC1小鼠中,使用DIP (30mg/kg) 治疗. 从28天到64天的年龄.
认知功能使用新型物体识别测试进行评估.
评估了运动功能,大脑病理和周围脂质积累.

主要成果:

在NPC1小鼠中,DIP治疗显著改善了识别记忆.
海马的calbindin表达是由DIP增加的.
DIP并没有改善运动功能,小脑病理或脏和肝脏中的脂质积累.

结论:

迪皮里达摩尔可以选择性地改善尼曼-皮克型C1小鼠的认知障碍.
DIP代表了NPC1的潜在治疗剂,可能用于组合疗法.

关键词:

尼曼 - 皮克C型的氨酸 (Adenosine) 是一种氨酸.卡尔宾丁 D28K 是一种二胺分子是什么意思在海马体内,海马体

更多相关视频

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology

Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology

Published on: March 23, 2011

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

相关概念视频

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.